Cargando…

Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor

PURPOSE: The role of platelets during myocardial ischemia/reperfusion (I/R) is ambivalent. They contribute to injury but also to cardioprotection. Repeated blood flow restriction and reperfusion in a tissue/organ remote from the heart (remote ischemic conditioning, RIC) reduce myocardial I/R injury...

Descripción completa

Detalles Bibliográficos
Autores principales: Lieder, Helmut Raphael, Tsoumani, Maria, Andreadou, Ioanna, Schrör, Karsten, Heusch, Gerd, Kleinbongard, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517043/
https://www.ncbi.nlm.nih.gov/pubmed/35595877
http://dx.doi.org/10.1007/s10557-022-07345-9
_version_ 1785109251205627904
author Lieder, Helmut Raphael
Tsoumani, Maria
Andreadou, Ioanna
Schrör, Karsten
Heusch, Gerd
Kleinbongard, Petra
author_facet Lieder, Helmut Raphael
Tsoumani, Maria
Andreadou, Ioanna
Schrör, Karsten
Heusch, Gerd
Kleinbongard, Petra
author_sort Lieder, Helmut Raphael
collection PubMed
description PURPOSE: The role of platelets during myocardial ischemia/reperfusion (I/R) is ambivalent. They contribute to injury but also to cardioprotection. Repeated blood flow restriction and reperfusion in a tissue/organ remote from the heart (remote ischemic conditioning, RIC) reduce myocardial I/R injury and attenuate platelet activation. Whether or not platelets mediate RIC’s cardioprotective signal is currently unclear. METHODS AND RESULTS: Venous blood from healthy volunteers (without or with pretreatment of 500/1000 mg aspirin or 180 mg ticagrelor orally, 2–3 h before the study, n = 18 each) was collected before and after RIC (3 × 5 min blood pressure cuff inflation at 200 mmHg on the left upper arm/5 min deflation). Washed platelets were isolated. Platelet-poor plasma was used to prepare plasma-dialysates. Platelets (25 × 10(3)/µL) or plasma-dialysates (1:10) prepared before and after RIC from untreated versus aspirin- or ticagrelor-pretreated volunteers, respectively, were infused into isolated buffer-perfused rat hearts. Hearts were subjected to global 30 min/120 min I/R. Infarct size was stained. Infarct size was less with infusion of platelets/plasma-dialysate after RIC (18 ± 7%/23 ± 9% of ventricular mass) than with platelets/plasma-dialysate before RIC (34 ± 7%/33 ± 8%). Aspirin pretreatment abrogated the transfer of RIC’s cardioprotection by platelets (after/before RIC, 34 ± 7%/33 ± 7%) but only attenuated that by plasma-dialysate (after/before RIC, 26 ± 8%/32 ± 5%). Ticagrelor pretreatment induced an in vivo formation of cardioprotective factor(s) per se (platelets/plasma-dialysate before RIC, 26 ± 7%/26 ± 7%) but did not impact on RIC’s cardioprotection by platelets/plasma-dialysate (20 ± 7%/21 ± 5%). CONCLUSION: Platelets serve as carriers for RIC’s cardioprotective signal through an aspirin-sensitive and thus cyclooxygenase-dependent mechanism. The P2Y(12) inhibitor ticagrelor per se induces a humoral cardioprotective signal. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10557-022-07345-9.
format Online
Article
Text
id pubmed-10517043
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105170432023-09-24 Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor Lieder, Helmut Raphael Tsoumani, Maria Andreadou, Ioanna Schrör, Karsten Heusch, Gerd Kleinbongard, Petra Cardiovasc Drugs Ther Original Article PURPOSE: The role of platelets during myocardial ischemia/reperfusion (I/R) is ambivalent. They contribute to injury but also to cardioprotection. Repeated blood flow restriction and reperfusion in a tissue/organ remote from the heart (remote ischemic conditioning, RIC) reduce myocardial I/R injury and attenuate platelet activation. Whether or not platelets mediate RIC’s cardioprotective signal is currently unclear. METHODS AND RESULTS: Venous blood from healthy volunteers (without or with pretreatment of 500/1000 mg aspirin or 180 mg ticagrelor orally, 2–3 h before the study, n = 18 each) was collected before and after RIC (3 × 5 min blood pressure cuff inflation at 200 mmHg on the left upper arm/5 min deflation). Washed platelets were isolated. Platelet-poor plasma was used to prepare plasma-dialysates. Platelets (25 × 10(3)/µL) or plasma-dialysates (1:10) prepared before and after RIC from untreated versus aspirin- or ticagrelor-pretreated volunteers, respectively, were infused into isolated buffer-perfused rat hearts. Hearts were subjected to global 30 min/120 min I/R. Infarct size was stained. Infarct size was less with infusion of platelets/plasma-dialysate after RIC (18 ± 7%/23 ± 9% of ventricular mass) than with platelets/plasma-dialysate before RIC (34 ± 7%/33 ± 8%). Aspirin pretreatment abrogated the transfer of RIC’s cardioprotection by platelets (after/before RIC, 34 ± 7%/33 ± 7%) but only attenuated that by plasma-dialysate (after/before RIC, 26 ± 8%/32 ± 5%). Ticagrelor pretreatment induced an in vivo formation of cardioprotective factor(s) per se (platelets/plasma-dialysate before RIC, 26 ± 7%/26 ± 7%) but did not impact on RIC’s cardioprotection by platelets/plasma-dialysate (20 ± 7%/21 ± 5%). CONCLUSION: Platelets serve as carriers for RIC’s cardioprotective signal through an aspirin-sensitive and thus cyclooxygenase-dependent mechanism. The P2Y(12) inhibitor ticagrelor per se induces a humoral cardioprotective signal. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10557-022-07345-9. Springer US 2022-05-21 2023 /pmc/articles/PMC10517043/ /pubmed/35595877 http://dx.doi.org/10.1007/s10557-022-07345-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Lieder, Helmut Raphael
Tsoumani, Maria
Andreadou, Ioanna
Schrör, Karsten
Heusch, Gerd
Kleinbongard, Petra
Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title_full Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title_fullStr Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title_full_unstemmed Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title_short Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor
title_sort platelet-mediated transfer of cardioprotection by remote ischemic conditioning and its abrogation by aspirin but not by ticagrelor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517043/
https://www.ncbi.nlm.nih.gov/pubmed/35595877
http://dx.doi.org/10.1007/s10557-022-07345-9
work_keys_str_mv AT liederhelmutraphael plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor
AT tsoumanimaria plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor
AT andreadouioanna plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor
AT schrorkarsten plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor
AT heuschgerd plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor
AT kleinbongardpetra plateletmediatedtransferofcardioprotectionbyremoteischemicconditioninganditsabrogationbyaspirinbutnotbyticagrelor